Maintaining 'standards' for biosimilar monoclonal antibodies

Nat Biotechnol. 2021 Mar;39(3):276-280. doi: 10.1038/s41587-021-00848-0.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Biosimilar Pharmaceuticals / standards*
  • Biosimilar Pharmaceuticals / therapeutic use
  • Drug Approval / legislation & jurisprudence
  • Drug Industry
  • Europe
  • Humans
  • United States
  • United States Food and Drug Administration

Substances

  • Antibodies, Monoclonal
  • Biosimilar Pharmaceuticals